Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
Clinical trial NCT05833984 · UNKNOWN
Trial details
- NCT number
- NCT05833984
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-17
- Primary completion
- 2024-02-07
- Enrollment
- 309
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.